Anti-TNFα therapy is employed in both colitis and Crohn's and NF-κB is constitutively active in human tumour samples from both CAC and sporadic CRC and is associated with poor prognosis [32–34]. This evidence concerns the gene NFKB1 and colorectal carcinoma.